Skip to main content
Premium Trial:

Request an Annual Quote

Aureus Pharma Joins European Biomed Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aureus Pharma said today that it will participate in the Biointelligence R&D Programme, a €118.2 million ($159.8 million) European consortium focused on promoting the use of systemic modeling and simulation tools for biomedical databases.

The Paris-based company said that it could receive an estimated €3.5 million for its participation in the program, under which it will contribute knowledge management and content development.

The Biointelligence R&D Programme is being coordinated by Dassault Systèmes and involves industry participants including Sanofi-Aventis, Ipsen, Servier, Pierre Fabre, Bayer Cropscience, and public research institutes such as Inserm, Inria, Genopole, and other partners.

Aureus said that the program also will enable it to evolve its data models to integrate more complex drug and drug candidate properties, biological protocols, or regulation of physiological responses.

The content Aureus will develop for the program will be focused in areas such as oncology, nuclear receptors, proteases, inhibitors, and life sciences semantics.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.